Ivana Magovčević-Liebisch, Vigil Neuroscience CEO
Vigil Neuroscience hits Wall Street with two ex-Amgen TREM2 agonists
Big Pharma largely abandoned neuroscience over the last several years — but the folks at Vigil Neuroscience believe a renaissance is around the corner, and apparently, so do investors.
The Cambridge, MA-based startup closed a $98 million IPO on Tuesday, pricing 7 million shares at $14, just below an expected $15 to $17 range. Most of that is going toward VGL101, an ex-Amgen TREM2 agonist in Phase I for a rare neurodegenerative disease.
To read Endpoints News become a free subscriber
Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters